TrialNature communications2026

Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial.

Dalong Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.